Diuretic response in acute heart failure: Clinical characteristics and prognostic significance

European Heart Journal

Volumn 35, Issue 19, 2014, Pages

  Valente, Mattia A E ^a   Voors, Adriaan A ^a   Damman, Kevin ^a   Van Veldhuisen, Dirk J ^a   Massie, Barrie M ^b   O'Connor, Christopher M ^c   Metra, Marco ^d   Ponikowski, Piotr ^e   Teerlink, John R ^b   Cotter, Gad ^f   Davison, Beth ^f   Cleland, John G F ^g   Givertz, Michael M ^h   Bloomfield, Daniel M ⁱ   Fiuzat, Mona ^c   Dittrich, Howard C ^j   Hillege, Hans L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF BRESCIA   (Italy)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f Momentum Research Inc   (United States)

^g UNIVERSITY OF HULL   (United Kingdom)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j UNIVERSITY OF IOWA   (United States)

more..

Author keywords

Cardiorenal syndrome; Diuretic resistance; Diuretics; Heart failure; Mortality; Prognosis; Rehospitalization; Renal dysfunction; Worsening renal function

Indexed keywords

BUMETANIDE; FUROSEMIDE; NITROGEN; PLACEBO; ROLOFYLLINE; TORASEMIDE; UREA; DIURETIC AGENT; SULFONAMIDE; XANTHINE DERIVATIVE;

ACUTE HEART FAILURE; ADULT; ADULT DISEASE; AGED; ARTICLE; CONTROLLED STUDY; DIURETIC RESPONSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL READMISSION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; WEIGHT CHANGE; WEIGHT REDUCTION; ACUTE DISEASE; ANALYSIS OF VARIANCE; ATHEROSCLEROSIS; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS; DRUG EFFECTS; DRUG RESISTANCE; DYSPNEA; HEART FAILURE; HYPOTENSION; KIDNEY FAILURE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANALYSIS OF VARIANCE; ATHEROSCLEROSIS; BUMETANIDE; DIABETES COMPLICATIONS; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DYSPNEA; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; HYPOTENSION; MALE; PATIENT READMISSION; RENAL INSUFFICIENCY; SULFONAMIDES; TREATMENT OUTCOME; WEIGHT LOSS; XANTHINES;

EID: 84901003001     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu065     Document Type: Article

References (49)

1. Adams KF Jr, FonarowGC, Emerman CL, LeJemtel TH, Costanzo MR, AbrahamWT, Berkowitz RL, Galvao M, Horton DP, ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-216.
2. Hall MJ, Levant S, Defrances CJ. Hospitalization for congestive heart failure: United States, 2000-2010. NCHS Data Brief 2012; 108:1-8.
3. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van GilstWH,Widimsky J, Freemantle N, Eastaugh J, Mason J, Study Group on Diagnosis of theWorking Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-463.
4. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, Murai K, Muanakata R, Yumino D, Meguro T, Kawana M, Nejima J, Satoh T, Mizuno K, Tanaka K, Kasanuki H, Takano T, ATTEND Investigators. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J 2010;159: 949-955.e1.
5. Hasselblad V, Gattis StoughW, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9:1064-1069.
6. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O'Connor CM, RichMW, Stevenson LW,Wang Y, Young JB, Krumholz HM. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331-338.
7. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006;27:1431-1439.
8. Yilmaz MB, Gayat E, Salem R, Lassus J, Nikolaou M, Laribi S, Parissis J, Follath F, Peacock WF, Mebazaa A. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail 2011;13:1244-1252.
9. NeubergGW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML,Wertheimer JH, Packer M, PRAISE Investigators. Prospective randomized amlodipine survival evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-38.
10. Mielniczuk LM, Tsang SW, Desai AS, Nohria A, Lewis EF, Fang JC, Baughman KL, Stevenson LW, Givertz MM. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail 2008;14:388-393.
11. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-869.
12. Aaser E, Gullestad L, Tollofsrud S, Lundberg J, Hall C, Djoseland O, Kjekshus J, Forfang K. Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure. Scand J Clin Lab Invest 1997;57:361-367.
13. Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996;28:376-382.
14. Kramer WG, Smith WB, Ferguson J, Serpas T, Grant AG III, Black PK, Brater DC. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. J Clin Pharmacol 1996; 36:265-270.
15. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM, NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797-805.
16. Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 2012;60:1031-1042.
17. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001;96:132-143.
18. Leto L, Aspromonte N, Feola M. Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review. Heart Fail Rev 2012.
19. Blair JE, Khan S, Konstam MA, Swedberg K, Zannad F, Burnett JC Jr, Grinfeld L, Maggioni AP, Udelson JE, Zimmer CA, Ouyang J, Chen CF, Gheorghiade M, EVEREST Investigators. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur Heart J 2009;30:1666-1673.
20. Kociol RD, McNulty SE, Hernandez AF, Lee KL, RedfieldMM, Tracy RP, Braunwald E, O'Connor CM, Felker GM, NHLBI Heart Failure Network Steering Committee and Investigators. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail 2013;6:240-245.
21. von Lueder TG, Atar D, Krum H. Diuretic use in heart failure and outcomes. Clin Pharmacol Ther 2013;94:490-498.
22. Weatherley BD, Cotter G, Dittrich HC, DeLucca P, Mansoor GA, Bloomfield DM, Ponikowski P, O'Connor CM, Metra M, Massie BM, PROTECT Steering Committee, Investigators, and Coordinators. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acutedecompensated heart failure and volume overload to assess treatment effect on congestion and renal function. J Card Fail 2010;16:25-35.
23. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC, PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-1428.
24. SmildeTD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;114:1572-1580.
25. Hammarlund MM, Paalzow LK, Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur J Clin Pharmacol 1984;26:197-207.
26. Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005; 46:2047-2051.
27. Brater DC. Diuretic therapy in congestive heart failure. Congest Heart Fail 2000;6: 197-201.
28. Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985;102: 314-318.
29. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995;57:601-609.
30. Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL. The cardiorenal syndrome in heart failure. Prog Cardiovasc Dis 2011;54:144-153.
31. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2013; doi: 10.1093/eurheartj/eht386.
32. van der Meer P, Postmus D, Ponikowski P, Cleland JG, O'Connor CM, Cotter G, Metra M, Davison BA, Givertz MM, Mansoor GA, Teerlink JR, Massie BM, Hillege HL, Voors AA. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol 2013;61:1973-1981.
33. Testani JM, ChenJ, McCauley BD, Kimmel SE, ShannonRP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010;122:265-272.
34. Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, Tang WH. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 2013; doi: 10.1161/CIRCHEARTFAILURE.113.000895.
35. Damman K, Kalra PR, Hillege H. Pathophysiological mechanisms contributing to renal dysfunction in chronic heart failure. J Ren Care 2010;36(Suppl. 1):18-26.
36. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874.
37. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation-mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 2012;32:1771-1776.
38. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17-22.
39. Valente MA, Damman K, Dunselman PH, Hillege HL, Voors AA. Urinary proteins in heart failure. Prog Cardiovasc Dis 2012;55:44-55.
40. Metra M, Davison B, Bettari L, Sun H, Edwards C, LazzariniV, Piovanelli B, CarubelliV, Bugatti S, Lombardi C, Cotter G, Dei Cas L. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 2012;5:54-62.
41. Ponikowski P, Mitrovic V, O'Connor CM, Dittrich H, Cotter G, Massie BM, Givertz MM, Chen E, Murray M,WeatherleyBD, Fujita KP, Metra M. Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. Eur J Heart Fail 2010;12:1238-1246.
42. Teerlink JR, Iragui VJ, Mohr JP, Carson PE, Hauptman PJ, LovettDH, Miller AB, Pina IL, Thomson S, Varosy PD, Zile MR, Cleland JG, Givertz MM, Metra M, Ponikowski P, Voors AA, Davison BA, Cotter G, Wolko D, Delucca P, Salerno CM, Mansoor GA, Dittrich H, O'Connor CM, Massie BM. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf 2012;35:233-244.
43. Voors AA, Dittrich HC, Massie BM, DeLucca P, Mansoor GA, Metra M, Cotter G, Weatherley BD, Ponikowski P, Teerlink JR, Cleland JG, O'Connor CM, Givertz MM. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol 2011;57:1899-1907.
44. Metra M, O'Connor CM, Davison BA, Cleland JG, Ponikowski P, Teerlink JR, Voors AA, Givertz MM, Mansoor GA, Bloomfield DM, Jia G, DeLucca P, Massie B, Dittrich H, Cotter G. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in thePROTECTStudy. Eur Heart J 2011; 32:1519-1534.
45. Campbell PT, Ryan J. Diuretic dosing in acute decompensated heart failure: lessons from DOSE. Curr Heart Fail Rep 2012;9:260-265.
46. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol 2012;59:2145-2153.
47. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999;100: 1311-1315.
48. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA, UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49:675-683.
49. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, Lewinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E, the Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:2296-2304.